The partnership between Sanofi and Regeneron notched another victory with the regulatory approval of Kevzara® (sarilumab) for rheumatoid arthritis (RA). This comes after the approval of Dupixent® in March 2017 for severe atopic dermatitis. On May 23, 2017, FDA approved Kevzara®, the interleukin (IL-6) receptor blocker, for moderate to severe RA in patients with an inadequate response to disease-modifying anti-rheumatic drugs (DMARDs). This comes after the initial disappointment of receiving a Complete Response Letter from FDA in late 2016 due to deficiencies in the manufacturing process.
As per American College of Cardiology (ACC) and American Heart Association (AHA), number of patients with CHF has gone up by 800,000 over five years and median age has dropped from 63 years to 55 years in last 20 years, with male preponderance.
Cancer remains the ultimate elusive frontier in medicine. Ironically, though the war on cancer has witnessed milestones with the discovery of p53 in the 70s, RAS in the 80s, genetic revolution in the 90s and the development of personalized medicine to address molecular mutations in the last decade, cancer remains incurable.
We have had an exhilarating year indeed!! 2016 has seen the successes of Tecentriq, Cinqair,and Taltz,the failures of Revusiran, Rociletinib, and Drisapersen,and Donald Trump step into the US presidency.
PharmGPS® Insights, is an Industry Newsletter that is a MUST read for any Biopharma Executive! Fortnightly issues offer high quality industry intelligence from PharmGPS®, a big data analytics and deep machine learning based artificial intelligence platform, that provides a real-time snapshot of emerging pipeline therapies for indications across all major therapeutic areas.